Table 9. Top 20 significant AKI-correlated medication pairs for two subgroups.
CKD, GFR<90 Group | Non-CKD GFR≥ 90 Group | ||||
---|---|---|---|---|---|
Medication Pairs | Pearson Coefficient | Medication Pairs | Pearson Coefficient | ||
Medication 1 | Medication 2 | Medication 1 | Medication 2 | ||
Acetazolamide | Fentanyl | 0.1106708 | Etomidate | Vancomycin | 0.13013489 |
Insulin* | Vasopressin* | 0.1042989 | Furosemide | Levofloxacin/Dext | 0.12517537 |
Calcium Chloride* | Vasopressin* | 0.10319643 | Heparin | Senna | 0.12332817 |
Heparin* | Norepinephrine* | 0.10296665 | Meropenem | Potassium Chloride | 0.12137292 |
Milrinone | Vasopressin | 0.09993951 | Furosemide** | Midazolam** | 0.12083589 |
Midazolam* | Vasopressin* | 0.09904047 | Metronidazole | Vasopressin | 0.11958312 |
Fentanyl* | Vasopressin* | 0.0989875 | Sodium Chloride | Vasopressin | 0.11876071 |
Fentanyl* | Norepinephrine* | 0.09895096 | Fentanyl | Levofloxacin/Dext | 0.11670254 |
Epinephrine | Vasopressin | 0.0981826 | Dopamine | Pantoprazole | 0.11633499 |
Propofol* | Vasopressin* | 0.09743555 | Furosemide | Vancomycin | 0.11594301 |
Acetazolamide | Potassium Chloride | 0.09513354 | Cefepime | Vasopressin | 0.1143419 |
Insulin | Milrinone | 0.0942025 | Etomidate | Piperacillin/Tazobactam Dextrose | 0.11387659 |
Amiodarone* | Vasopressin* | 0.09379757 | Etomidate | Pot Chloride | 0.11345592 |
Calcium Chloride | Milrinone | 0.09313112 | Midazolam** | Vancomycin** | 0.11332864 |
Magnesium Sulfate* | Vasopressin* | 0.09185513 | Etomidate | Furosemide | 0.11209237 |
Epinephrine | Milrinone | 0.09170968 | Etomidate | Phenylephrine | 0.11147296 |
Insulin* | Midazolam* | 0.09148049 | Etomidate | Vasopressin | 0.11103668 |
Acetazolamide | Lorazepam | 0.08859342 | Vancomycin | Vasopressin | 0.11098672 |
Potassium Chloride | Vasopressin | 0.08796814 | Norepinephrine** | Piperacillin/Tazobactam Dextrose** | 0.11006394 |
Acetazolamide | Furosemide | 0.08789809 | Norepinephrine | Sodium Chloride | 0.10801834 |
* AKI-associated medication pairs that were common between the CKD subgroup and the whole cohort.
** AKI-associated medication pairs that were common between the non-CKD subgroup and the whole cohort.